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We examined clinical and nutritional predictors of weight change over two consecutive 6-month intervals among 99 HIV-positive
male injection drug users initiating antiretroviral therapy (ART) in Hanoi, Vietnam. The average weight gain was 3.1 ± 4.8kgin
the ﬁrst six months after ART and 0.8 ± 3.0kg in the following six months. Predictors of weight change diﬀered by interval. In
the ﬁrst interval, CD4 < 200cells/μL, excellent/very good adherence to ART, bothersome nausea, and liquid supplement use were
all associated with positive weight changes. Moderate to heavy alcohol use and tobacco smoking were associated with negative
weight changes. In the second interval, having a CD4 count <200cells/μL at the beginning of the interval and tobacco smoking
weretheonlysigniﬁcantpredictorsandbothwereassociatedwithnegativeweightchanges.Weidentiﬁedseveralpotentialareasfor
interventions to promote weight gain immediately after starting ART in this population. Studies are needed to determine whether
improving weight prior to, or at, ART initiation will result in improved outcomes on ART.
1.Introduction
Access to antiretroviral treatment (ART) has expanded
rapidly in many moderate-to low-income countries aﬀected
by the HIV epidemic. In addition to reducing mortality
rates, ART has many favorable eﬀects among people living
with HIV (PLHIV), such as improving weight and lean
body mass, particularly in patients with greater pretreatment
immunological and virological compromise [1, 2]. Several
large-scaleARTprogramsinsub-SaharanAfricaindicatethat
malnutrition (low BMI) at the start of ART is signiﬁcantly
and independently associated with subsequent mortality [3–
6], while weight gain after ART is associated with survival
[7, 8]. It is unclear whether this association is causal.
Although weight changes appear to parallel the success
of ART, it is unknown whether interventions to improve
weight prior to or at ART initiation will improve subsequent
outcomes.
In Vietnam, the number of PLHIV is estimated to be
293,000 with an HIV prevalence rate of 0.53% among adults
[9]. Injection drug use (IDU) remains the main driver of
HIV in Vietnam. The HIV prevalence rate among IDUs is
estimatedtobe30%overall,withratesofover50%inHoChi
Minh City and Quang Ninh [10]. In Hanoi, the most recent
estimates of HIV among IDUs are around 25% [9]. Rapid
scale-upofARTinVietnambeganin2005withsupportfrom
the Vietnam Ministry of Health,the United StatesPresident’s
Emergency Plan for AIDS Relief (PEPFAR), and the Global
Fund. To our knowledge, no studies are published on the
nutritional outcomes of ART initiation in Vietnam.
The primary objective of this analysis was to determine
predictors of weight change six to 12 months after initiation
of ART among IDUs in Hanoi. Our results will help develop
and determine the appropriate timing of targeted nutritional
interventions in Vietnam, paving the way for future trials to
test the impact of improving weight on ART outcomes.2 AIDS Research and Treatment
2. Methods
2.1. Study Population. The HIV/AIDS outpatient clinic at
the National Hospital of Tropical Diseases (NHTD) in
Hanoi, Vietnam is a PEPFAR-supported clinic providing
ART to approximately 800 HIV-infected patients. Between
August 2006 and December 2008, 100 HIV-positive, ART-
na¨ ıve patients were recruited from the outpatient clinic at
NHTD into an ongoing longitudinal study on the causes
and consequences of malnutrition in HIV-infection. Patients
were eligible if they were HIV seropositive, between the ages
of 18 and 65, had a history of IDU within the previous
ﬁve years, were eligible to start ART, understood the study
procedures, and signed informed consent. Since there were
few female drug users in the clinic population at the time of
recruitment,thestudypopulationwasrestrictedtomenonly.
Study participants are followed every 6 months for 3 years.
For the current analysis, we include data from the baseline,
6 month, and 12 month study visits. One participant was
excluded from this analysis because of missing questionnaire
data at baseline.
This study was reviewed and approved by the Institu-
tional Review Boards of the Tufts School of Medicine and the
Hanoi School of Public Health.
2.2. Data Collection. Data collected at each study visit
included a brief physical examination, body composition
measurements, dietary intake, and a lifestyle questionnaire.
The lifestyle questionnaire elicited information on sociode-
mographics; medical history; alcohol, tobacco, and drug use;
use of ART and other prescribed medications; adherence to
ART; food insecurity. Adherence to ART was assessed by
the patient’s subjective rating of how well he was able to
take all of his prescribed HIV medications in the past 30
days using a 5-point Likert scale with responses of excellent,
very good, good, fair, or poor [11]. Food insecurity was
measured using a modiﬁed version of the USDA’s short form
of the household food security scale [12]. Dietary intake was
estimated by a 24-hour recall. Anthropometric assessments
includedweight,height,andskinfoldmeasurements(triceps,
suprailiac, and subscapular). Fat mass was calculated using
the equations of Durnin and Womersley [13]. Fat-free mass
(FFM) was obtained by subtracting fat mass from total
bodyweight.Dietaryintakeandanthropometricassessments
were administered by study personnel who were trained
and standardized regularly by a research dietitian. At each
study visit, blood was collected for the determination of
complete blood count, CD4 cell count, and HIV viral
load.
2.3. Statistical Analysis. Using a repeated measures regres-
sion model, we identiﬁed clinical and nutritional predictors
of weight change over two consecutive 6-month intervals
(Interval 1: pre-ART to 6 months post-ART; and Interval 2: 6
to 12 months post-ART). The unit of analysis was person-
intervals. The term “interval baseline” is deﬁned as the
baseline (pre-ART) visit for Interval 1 and the 6 month visit
for Interval 2. The outcome of interest was weight change
over the interval.
We examined several time-varying predictors of weight
change including CD4 count (cells/μL), log viral load
(copies/ml), drug use in the previous 6 months (yes/no),
hepatitis C coinfection (yes/no), TB coinfection (yes/no),
energy intake (total kilocalories from food and supple-
ments),carbohydrateintake(grams),ﬁberintake(gramsand
grams/kg body weight), protein intake (grams and grams/kg
body weight), total fat intake (grams), food insecurity
(yes/no), adherence to ART (Excellent/Very Good versus
Good/Fair/Poor), intake of liquid supplements (yes/no),
and general symptoms of illness (thrush, mouth sores,
nausea, vomiting, diarrhea, stomach pain, and fever). Liquid
supplement use was deﬁned as any report of intake of
Ensure liquid supplements, Oresol (oral glucose-electrolyte
solution), glucose, or sweetened condensed milk which was
not part of a meal or other drink. Symptoms of illness were
categorized as “yes” only if participants reported that they
were bothered by the symptom moderately, quite a bit, or
extremely. Moderate/heavy drinking was categorized as “yes”
when participants drank ≥4 days per week and/or had 3 or
more drinks on the days they drank. All of these variables
were measured at the interval baseline, with the exception
of adherence to ART, which was taken at the end of the
interval since patients were reporting their adherence levels
during the previous 6 months. Tobacco smoking (yes/no)
was assessed at the baseline visit only. In addition, changes
in CD4+ cell count and log viral load over the interval
were examined as potential correlates of weight change,
while baseline (pre-ART) body mass index (BMI; weight (in
kg)/height (in m2)) was examined as a potential confounder.
All statistical analyses were carried out using the SAS
statistical software (SAS Institute, Cary, NC, Version 9.2).
Repeated measures analyses were performed using PROC
MIXED in SAS. To determine if the predictors of weight
change diﬀered by interval, interaction terms of each poten-
tial predictor with an indicator variable for “interval” were
examined in the models. Since several of these interaction
terms were signiﬁcant in the ﬁnal model, for ease of
interpretation, the model results are presented separately
by interval in Table 3 with standard errors and P-values
obtained from the Estimate statement in PROC MIXED.
3. Results
Table 1 shows the sociodemographic and clinical charac-
teristics for the 99 men that were assessed at the baseline
study visit only. The average age was 32 years. The majority
(69%) were married and had 10 or more years of education
(79%). Approximately one-third had been imprisoned in
their lifetime. Nearly 80% reported current tobacco smoking
and almost all of the men (92%) tested positive for Hepatitis
C infection. All participants were started on ART approxi-
mately 2 weeks after study entry. Most (59%) were started
on ZDV/3TC/EFV. For this analysis, we did not take into
account any treatment changes or interruptions over the 12
month followup period, which were very few.
By one year after starting ART, 8 men had died (7 in the
ﬁrst 6 months), 10 men were lost to follow-up, 3 were jailed,
and 4 had transferred to another clinic. Thus, of theAIDS Research and Treatment 3
Table 1: Characteristics measured at baseline study visit only for 99
HIV-positive men recruited from the National Hospital of Tropical
Diseases (NHTD) in Hanoi, Vietnam.
Baseline characteristic Mean ± SD or N(%)
Age 31.7 ± 4.8
Marital Status1
Never married 22 (22%)
Married 68 (69%)
Divorced/Sep/Widowed 8 (8%)
Education
<9y e a r s 2 1( 2 1 % )
10–12 years 43 (43%)
Vocational 18 (18%)
University or more 17 (17%)
Jail or prison (ever) 31 (31%)
Tobacco smoking1 77 (79%)
Hepatitis C 91 (92%)
Initial ART Regimen2
ZDV/3TC/EFV 48 (59%)
ZDV/3TC/NVP 19 (23%)
D4T/3TC/NVP 9 (11%)
D4T/3TC/EFV 4 (5%)
DDI/ABC/KAL 1 (1%)
Abbreviations: ZDV: zidovudine; 3TC, lamivudine; EFV: efavirenz; NVP:
Nevirapine; D4T: stavudine; ABC: abacavir; KAL: kaletra.
1n = 98.
2n = 81.
100 patients enrolled, 81 and 75 had data available for
analysis from their 6 and 12 month follow-up visits, respec-
tively. Table 2 shows participant characteristics that were
measured at each of the three study visits. Nearly half (47%)
reported using any drugs (injection or noninjection) and
24% reported injection drug use in the six months prior to
recruitment.Ratesdecreasedovertimeforbothtypesofdrug
use. While rates of moderate/heavy alcohol use decreased
slightly, rates of light drinking increased substantially over
time. There were very few reports of food insecurity at any
of the study visits. Both CD4 counts and viral load improved
over time. Body mass index (BMI) also improved over time.
At baseline, BMI was less than 18.5kg/m2 for 39% of our
study participants, compared with 23.5% among men of the
same age group living in the region [14]. By 12 months
post-ART, only 17% of the men had BMI levels <18.5kg/m2.
Reports of general symptoms of illness decreased from pre-
to post-ART, while energy intake remained constant. The
proportion adhering well to ART decreased from 6 to 12
months post-ART.
3.1. Treatment Outcomes at 6 and 12 Months after ART
Initiation. Table 3 shows the average change for several
continuousvariablesovereachinterval.Bothimmunological
and virological responses were favorable. The mean increase
in CD4 counts was 66 cells/μLi nI n t e r v a l1a n d3 2c e l l s / μL
in Interval 2, resulting in mean CD4 levels of 160cells/μL
(median = 137cells/μL) after six months on treatment and
Table 2: Characteristics measured at each study visit for 99 HIV-
positive men recruited from the National Hospital of Tropical
Diseases (NHTD) in Hanoi, Vietnam.
Study visit (Mean ± SD or N (%))
Baseline
(pre-ART)
(n = 99)
6m o n t h
(n = 81)
12 month
(n = 75)
Any drug use in last 6
months1 47 (47%) 26 (33%) 22 (30%)
Injection drug use in
last 6 months1 24 (24%) 10 (13%) 8 (11%)
Alcohol2
Nondrinker 52 (53%) 30 (38%) 23 (31%)
Light drinker 26 (27%) 36 (45%) 40 (54%)
Moderate or heavy
drinker 20 (20%) 14 (18%) 11 (15%)
Food insecurity2 5( 5 % ) 2( 3 % ) 3( 4 % )
CD4 count (cells/μL) 96.7 ± 67.6 160.3 ±
114.7
194.6 ±
144.5
CD4 <200 cells/uL 88 (89%) 61 (75%) 46 (61%)
Log viral load
(copies/mL)3 4.9 ± 1.0 2.1 ± 1.0 1.9 ± 0.8
Viral load <1000
copies (%)3 7 (7%) 70 (86%) 67 (92%)
Weight (kg) 52.9 ± 7.1 56.5 ± 7.8 57.3 ± 8.0
BMI (kg/m2) 19.1 ± 2.1 20.4 ± 2.3 20.8 ±2.3
BMI categories
< 17.0kg/m2 15 (15%) 4 (5%) 0 (0%)
17.0 to
<18.5kg/m2 24 (24%) 15 (19%) 13 (17%)
18.5 to <20kg/m2 26 (26%) 22 (27%) 16 (21%)
≥ 20.0kg/m2 34 (34%) 40 (49%) 46 (61%)
Bothersome nausea1 46 (46%) 11 (14%) 15 (20%)
Bothersome
Diarrhea1 20 (20%) 1 (1%) 1 (1%)
Bothersome fever1 62 (63%) 12 (15%) 13 (18%)
Energy intake
(kcals/day)4 2108 ± 755 2015 ± 799 2192 ± 780
Excellent/Very Good
Adherence to ART5 — 60 (76%) 51 (69%)
1n = 80 for 6 month visit and n = 74 for 12 month visit.
2n = 98 for baseline, n = 80 for 6 month visit, and n = 74 for 12 month
visit.
3n = 73 for 12 month visit.
4n = 69 for 12 month visit.
5n = 79 for 6 month visit and 74 for 12 month visit.
195cells/μL (median = 171cells/μL) after 12 months. How-
ever, at the end of 12 months on treatment, 61% (46/75)
still had CD4 counts <200, 19% had CD4 <100 (14/75),
and 3% (2/75) had CD4 < 50cells/μL (data not shown).
HIV viral load levels decreased by nearly three logs in
the ﬁrst six months and remained stable over the next 6
months. By 12 months of treatment, 92% had viral load
levels <1000copies/mL and 77% had levels <50copies/mL.4 AIDS Research and Treatment
Table 3: Average changes in selected variables over each six month interval.
Mean ± SD (P-value)
Interval 1: Interval 2:
pre-ART to 6 months post-ART 6 to 12 months post-ART
(N = 81) (N = 75)
CD4 count (cells/μL) 65.6 ± 97.2 (<0.001) 32.4 ± 101.0 (0.01)
Log Viral Load (copies/mL) −2.8 ± 1.5 (<0.001) −0.1 ± 0.9 (0.28)
Weight (kg) 3.1 ± 4.8 (<0.001) 0.8 ± 3.0 (0.02)
% Weight change 6.2 ± 9.6 (<0.001) 1.3 ± 5.5 (0.01)
BMI (kg/m2)1 . 1 ± 1.7 (<0.001) 0.3 ± 1.1 (0.05)
Fat-free mass (kg) 1.5 ± 3.0 (<0.001) 0.5 ± 2.3 (0.05)
Fat-free mass (%) −1.7 ± 4.0 (<0.001) −0.3 ± 3.2 (0.48)
Fat mass (kg) 1.6 ± 2.9 (<0.001) 0.3 ± 2.3 (0.27)
Fat mass (%) 1.7 ± 4.0 (<0.001) 0.3 ± 3.2 (0.48)
AverageweightandBMIincreasedsigniﬁcantlyoverboth
intervals, but the increases were more substantial in the
initial 6 months after starting ART. The increase in weight
was approximately equally divided between increases in fat
and fat-free mass. Percent fat increased signiﬁcantly only in
the ﬁrst 6 months.
3.2. Predictors of Weight Change. Many of the potential
predictors we examined were associated with weight change
in the unadjusted regression models (data not shown). In
the ﬁnal multivariate model, several predictors remained sig-
niﬁcantly and independently associated with weight change.
These variables are listed in Table 4. In cases where “interval”
was considered a signiﬁcant eﬀect modiﬁer (all predictors
except for tobacco smoking), coeﬃcients are presented
and interpreted separately for Interval 1 and Interval 2 as
described in Methods. In Interval 1, all of these predictors
were signiﬁcantly associated with a positive weight change,
except for moderate/heavy drinking, which was signiﬁcantly
associated with negative weight change. In Interval 2, how-
ever, none of these covariates were associated with weight
change, except for CD4 < 200 at the interval baseline, which
wasnowsigniﬁcantlyassociatedwithnegativeweightchange.
Tobacco smoking had the same negative eﬀect on weight
change in both intervals (β = −1.2kg; P =.02). Energy intake
and food insecurity were not independently associated with
weight change in either interval.
Figures 1(a)–1(d) shows the net weight gain/loss by
interval for presence and absence of several of the covariates
as predicted by the ﬁnal regression model. For each ﬁgure,
the values assumed for the other covariates in the model
are delineated in the ﬁgure title. Figure 1(a) shows that
participants with CD4 < 200 at the start of ART are
predicted to gain, on average, over 2.6kg in the ﬁrst 6
months of treatment, while those with CD4 ≥200 are
predicted to lose over 0.8kg during that same interval.
This diﬀerence of nearly 3.5kg is statistically signiﬁcant.
In Interval 2, the reverse is seen with signiﬁcantly larger
weightgainamongthosewithCD4counts ≥200.Figure 1(b)
shows the predicted net weight changes by interval for
those with Excellent/Very Good adherence to ART compared
to those with Good/Fair/Poor adherence. In the ﬁrst 6
months of ART, those with Excellent/Very Good adherence
are predicted to gain 2.6kg weight, while those reporting
Good/Fair/Poor adherence are predicted to lose 0.4kg. In the
second interval, only very slight weight losses are predicted
for both levels of adherence. In Figure 1(c), we see that
moderate to heavy alcohol intake has a signiﬁcant negative
eﬀect on weight gain in the ﬁrst six months after initiation of
ART with none/light drinkers gaining 2.6kg of weight, while
moderate/heavy drinkers gained only 0.1kg. There was,
however, no diﬀerence in weight change by alcohol intake
6 to 12 months later. Conversely, use of liquid supplements
had a signiﬁcant positive eﬀe c to nw e i g h tg a i ni nI n t e r v a l1
(people takingliquidsupplementsgained5.2kgversus2.6kg
weight gain in all others), but not in Interval 2 (Figure 1(d)).
4. Discussion
Overall, ART outcomes were encouraging in this population
of Vietnamese men with a history of IDU. CD4 counts
increased by 66 cells/μL after six months and by 98 cells/μL
after 12 months. HIV viral load decreased signiﬁcantly,
resulting in 92% of the men being virally suppressed (<1000
copies/ml) after 12 months on therapy. Signiﬁcant increases
in weight were observed, particularly in the ﬁrst 6 months of
therapy.
The pattern of weight gain we observed appears to be
consistent with previous reports, with the highest rate of
weight gain occurring in the ﬁrst six months after ART
initiation, then stabilizing afterwards. In a combined analysis
of patients in ART programs in Cambodia (n = 2451) and
Kenya (n = 2618),Madecetal.[8]observedasimilarpattern
of weight gain, although patients in that study continued
to gain weight up to 12 months post-ART before weights
stabilized. The amount of weight gain we observed over the
initialsixmonths(3.1 ±4.8kg)isalsosimilartoreportsfrom
other populations. In 488 patients initiating ART in four
African countries (Ethiopia, Kenya, Rwanda, and Uganda),
an average weight gain of 3.9 ± 5.1kg over 6 months wasAIDS Research and Treatment 5
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Figure 1: Predicted weight changes by interval for men with and without speciﬁc characteristics. (a) Values for other covariates are:
Adherence = Excellent/Very Good, Nausea = no, Moderate/Heavy Drinking = no, Liquid supplements = no, and Tobacco smoking = yes. (b)
Values for other covariates are: CD4 < 200 = yes, Nausea = no, Mod/Heavy Drinking = no, Liquid supplements=no, and Tobacco smoking=
yes. (c) Values for other covariates are: CD4 < 200 = yes, Adherence = Excellent/Very good, Nausea = no, and Liquid supplements = no,
and Tobacco smoking = yes. (d) Values for other covariates are CD4 < 200 = yes, Adherence = Excellent/Very good, Nausea = no, and
Moderate/Heavy drinking = no, and Tobacco smoking = yes.
Table 4: Coeﬃcients derived from ﬁnal multivariate model predicting weight change, accounting for eﬀect modiﬁcation by Interval.
Diﬀerence in weight change (β) ± SE (P-value) P-value for interaction term
Interval 1 Interval 2
Intercept −2.7 ± 1.8 (.14) 4.1 ± 0.9 (<.001) 0.001
CD4 <200 cells/μL( y e s / n o ) 3 . 5±1.5 (.03) −3.0 ± 0.7 (<.001) <0.001
Adherence to HIV meds
(Excellent/Very Good versus
Good/Fair/Poor)
3.0 ± 0.9 (.002) −0.01 ± 0.7 (.98) 0.01
Nausea (yes/no) 2.2 ± 0.8 (.006) −1.3 ± 0.8 (.13) 0.005
Moderate/Heavy Drinker
(yes/no)
−2.6 ± 1.0 (.02) −0.02 ± 0.8 (.98) 0.06
Liquid supplements (yes/no) 2.6 ± 1.0 (.01) −1.3 ± 1.5 (.39) 0.05
Tobacco smoking −1.2 ± 0.5 (.02) 0.17
Interaction term (Tobacco smoking ∗ Interval) was dropped from the ﬁnal model due to nonsigniﬁcant P-value. Coeﬃcient shown is from main eﬀect of
tobacco smoking only.6 AIDS Research and Treatment
recorded [15]. In India, investigators reported an average
weight gain of 2.8 ± 5.4 kg over 6 months in 190 patients
starting ART [16]. In 185 Nigerian patients followed up for
two years, the average weight of the group increased from
52kg pre-ART to 59kg post-ART [17]. In comparison, the
average weight in our cohort increased from 53kg pre-ART
to 57 kg after one year post-ART.
We also observed some diﬀerences in our population
compared to previous publications. In terms of BMI, Barth
et al. [18] reported an average BMI increase of 2.4kg/m2
after 6 months on ART and 3.5kg/m2 after 12 months
among patients initiating ART in South Africa. We observed
an average BMI increase of only 1.1kg/m2 after 6 months
and 1.4kg/m2 after 12 months post-ART. One reason for
this diﬀerence could be that BMI at baseline was slightly
higher (less room to improve) in our participants (median =
19.2kg/m2) compared to the male participants in the Barth
study (median = 18.6kg/m2); however patients in the Barth
study achieved a BMI level of 23.4kg/m2 after 12 months
on ART, whereas our participants achieved a BMI level of
only 20.8kg/m2 after 12 months. Another reason is that the
Barth study focused on a population where the primary
mode of HIV transmission is heterosexual, whereas ours was
a population of injection drug users where other related risk
factors (behavioral and/or biological) could inhibit optimal
weight gain. In addition, although two previous studies
reportedthatpatientswithlowerBMIatARTinitiation(≤16
or ≤17) had larger weight gains than those with higher BMI
[8, 19], baseline BMI was not associated with weight change
in our population.
We found several signiﬁcant predictors of weight gain,
particularly in the ﬁrst six months after ART initiation.
Patients with more advanced HIV infection at baseline (CD4
cell counts <200 cells/μL) were more likely to have positive
weight changes in the ﬁrst six months of therapy, likely due
to the beneﬁcial eﬀects of ART. However, six months after
start of ART, patients with CD4 < 200 cells/μL( as i g no f
continued immunosuppression) had signiﬁcantly less weight
change over the following six months compared to those
with CD4 ≥ 200. The vast majority (92%) of our patients
startedARTwithCD4counts<200cells/μL.Ofthese,87%of
patients whose CD4 counts improved to ≥200 cells/μLa f t e r
6 months of therapy gained weight, while only 48% of those
with continued immunosuppression after 6 months gained
weight.
In our cohort, “Excellent” to “Very Good” adherence to
ART medications was signiﬁcantly associated with positive
weight change in the ﬁrst six months of therapy. Similarly,
Ross-Degnan et al. found that adherence was signiﬁcantly
associated with weight gain over the ﬁrst 9 months after ART
initiation in four African countries [15]. In our study, after
six months of therapy, excellent/very good adherence was no
longer independently associated with positive weight change
after taking into account the positive eﬀect of CD4 counts
rising to ≥200 cells/μL.
We found that bothersome nausea at baseline (reported
by 49% of participants) was associated with weight gain
in the ﬁrst 6 months of ART. While this may seem to be
counterintuitive, we can speculate that having bothersome
nausea at baseline (pre-ART) is a symptom of illness
contributing toreduced food intake, and whenthese patients
initiate ART their symptoms resolve and they are able to
eat more and gain more weight. In the second interval, the
15% who reported bothersome nausea (post-ART) had a
negative weight change (although not statistically signiﬁcant
(P = .13)). At this point in time, continued nausea or nausea
from side eﬀects of the medications may inhibit a patients’
ability to gain weight.
The use of liquid supplements was a signiﬁcant predictor
of weight gain in the ﬁrst six months of ART and therefore
may have potential as a nutritional intervention for weight
gain (or reducing weight loss) in this population. No
other dietary factors were associated with weight change,
indicating that a dietary supplement may be necessary.
Liquid supplements were primarily Ensure or Oresol (a
glucose-electrolyte solution). While Ensure is known as a
balanced nutritional supplement, Oresol is generally used
as a treatment for dehydration or diarrhea and has little
nutritional value beyond its sugar and electrolyte content.
The other two types of liquid supplements that were
reported in this population (glucose solution and sweetened
condensed milk) contribute high amounts of calories from
carbohydrates and sugars assisting in weight gain, but have
minimal nutrient content. More in-depth information is
needed before planning a nutritional intervention with a
liquid supplement, such as the reasons why patients were
taking these supplements, how much and how often they
were taking them, and whether they were taking them on
their own or as prescribed by a doctor. Fundamentally,
we still need to understand whether weight gain by any
means is associated with improved outcomes on ART, or
if nutritionally balanced supplements are more likely to
be successful. We were not able to examine this in our
population because we did not have enough patients taking
each of the diﬀerent types of supplements.
Anotherinterestingﬁndingfromourstudyisthatalcohol
intake was associated with negative weight gain in the ﬁrst
six months after ART initiation in the ﬁrst interval, but not
the second. While nutritional status in alcoholics has been
described in the United States and Western Europe [20–
24], the nutritional impact of alcohol abuse has not been
studiedinapopulationwithmarginalnutritionalstatussuch
as our population of drug users with HIV in Vietnam. In
addition, the eﬀects of alcohol abuse on the liver are more
marked in persons with chronic viral hepatitis [25–27]. This
is of particular concern in our population where 92% are
coinfected with Hepatitis C. Twenty percent of our popu-
lation reported moderate to heavy amounts of alcohol use
at baseline and this group had signiﬁcantly less weight gain
thannon-tolightdrinkers.Furtherresearchisneededonthe
speciﬁc nutritional, biological, and/or behavioral eﬀects of
alcohol use in this population to determine the mechanism
through which it reduces weight change. Similarly tobacco
smoking had a signiﬁcantly negative eﬀect on weight change
in both intervals. Since the vast majority (∼80%) of our
study population reported tobacco smoking at baseline, this
would be another high-priority area for research, including
the testing of smoking cessation interventions.AIDS Research and Treatment 7
Our study had some limitations. First, our results may
not be generalizable to populations where injection drug
use is not the major mode of HIV transmission. Injection
drug users may have additional complications predisposing
to weight loss, such as cytokine-mediated weight loss due
to sepsis and infections and/or psychiatric comorbidities
(e.g., depression, euphoria, behavioral abnormalities, and
memory disturbances) that may aﬀect food choices and
eating patterns. Second, this study did not take into account
the eﬀect of other medical comorbidities potentially associ-
ated with weight change, such as opportunistic infections,
inﬂammatory states, cancers, and malabsorption. We were
not able to obtain standardized clinical diagnoses of medical
co-morbidities in this study as diagnostic tests for these con-
ditions are not generally available to this patient population
and the physicians do not routinely look for these during
their ART visits. However, we did include self-reports of TB
and Penicillium marneﬀei diagnoses on the questionnaire,
butfoundveryfewparticipantswhoreportedthese.Finally,a
single 24-hour dietary recall to assess dietary intake is a lim-
itation as this may not accurately reﬂect typical daily intake
overtheprevious6or12months.Wefeltthatthismethodfor
assessment of dietary intake was best suited for this popula-
tion in Vietnam as it is less of a burden to study participants
compared to the food diaries, and we were not aware of a
validated food frequency questionnaire in Vietnam. We did
ask participants whether the 24-hour recall was reﬂective of
their usual intake, considerably more, or considerably less
than their usual intake and 70–80% of participants at 6 and
12monthsreportedthatitwasreﬂectiveoftheirusualintake.
In summary, we found that signiﬁcant weight gain was
achieved in the ﬁrst 6 months after ART initiation, and then
stabilized over the next 6 months. While this is a positive
result, some improvements are still needed. Although 39%
were classiﬁed as underweight at baseline, only 28% of our
participants gained at least 10% of their baseline weight
(an indicator of treatment success used by some ART
clinics) by six months after ART initiation, and only one
additional person reached this endpoint by 12 months. More
research is needed to determine why weight gain did not
continue after 6 months of therapy, particularly when a
signiﬁcantproportionofpatientsinthispopulationwerestill
underweight (BMI < 18.5). In addition, the magnitude of
CD4 change over 6 and 12 months of ART use was less than
that reported in other populations and this requires further
investigation. The fact that having a CD4 < 200 cells/μLa t6
months post-ART was associated with continued weight loss
(or a reduction in weight gain) in the following six months
suggests that eﬀorts should be made to diagnose and treat
patients earlier, before their CD4 levels drop too far below
200 cells/μL that they remain under this threshold after six
months of therapy.
This study is the ﬁrst step towards developing targeted
interventions to improve nutritional and immunological
outcomes on ART in drug users in Vietnam. We identiﬁed
several potential areas for interventions to promote weight
gain in this population. Studies are still needed to determine
whether improving BMI prior to ART initiation will reduce
early mortality rates.
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